Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours
- PMID: 19317849
- DOI: 10.1111/j.1600-0714.2009.00770.x
Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours
Abstract
Objective: The aim of this study was to determine epidermal growth factor receptor (EGFR) expression in malignant salivary gland tumours and its possible relationships with clinical and morphological findings, disease course and prognosis.
Patients and methods: The study sample comprised 88 patients diagnosed and treated for primary malignant salivary gland tumours between January 1992 and December 2002. We analysed EGFR expression using immunohistochemistry on formalin-fixed, paraffin embedded surgical specimens of all patients. Statistical analysis was used to investigate possible relationships between EGFR expression and clinical findings, histological findings, disease course and patients survival.
Results: Of all cases, 32 (36.4%) were EGFR positive. There was a statistically significant correlation between EGFR expression and histological grade. No other variable was correlated with EGFR expression including the overall and disease-free survival. Stage classification was the only parameter in multivariate analysis that was an independent predictor of low overall and disease-free survival.
Conclusion: EGFR is not a useful indicator of prognosis in malignant salivary gland tumours. However, the EGFR expression in salivary gland cancers like adenocarcinomas, undifferentiated carcinomas, mucoepidermoid carcinomas or salivary duct carcinomas suggests that these tumours may be a candidate for therapy investigation directed at EGFR.
Similar articles
-
DNA content in malignant salivary gland tumours.Oral Dis. 2009 May;15(4):295-301. doi: 10.1111/j.1601-0825.2009.01525.x. Epub 2009 Mar 23. Oral Dis. 2009. PMID: 19320959
-
Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study.J Oral Maxillofac Surg. 2010 Oct;68(10):2489-96. doi: 10.1016/j.joms.2009.09.065. Epub 2010 Aug 1. J Oral Maxillofac Surg. 2010. PMID: 20678839
-
Management of nasopharyngeal salivary gland malignancy.Laryngoscope. 2001 Sep;111(9):1533-44. doi: 10.1097/00005537-200109000-00009. Laryngoscope. 2001. PMID: 11568602
-
Mucoepidermoid carcinoma of minor salivary glands: a clinical study of 16 cases and review of the literature.Oral Dis. 2006 Jul;12(4):364-70. doi: 10.1111/j.1601-0825.2005.01166.x. Oral Dis. 2006. PMID: 16792720 Review.
-
Distant metastasis of parotid gland tumors.Acta Otolaryngol. 2006 Apr;126(4):340-5. doi: 10.1080/00016480500401035. Acta Otolaryngol. 2006. PMID: 16608783 Review.
Cited by
-
Prognostic and clinical implications of c-erbB-2 expression in patients with oral cancer: A meta-analysis.Medicine (Baltimore). 2020 Jun 5;99(23):e20575. doi: 10.1097/MD.0000000000020575. Medicine (Baltimore). 2020. PMID: 32502026 Free PMC article.
-
Genetic alterations in salivary gland cancers.Cancer. 2016 Jun 15;122(12):1822-31. doi: 10.1002/cncr.29890. Epub 2016 Feb 29. Cancer. 2016. PMID: 26928905 Free PMC article. Review.
-
Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade.Strahlenther Onkol. 2012 Jun;188(6):518-22. doi: 10.1007/s00066-012-0096-1. Epub 2012 Apr 12. Strahlenther Onkol. 2012. PMID: 22526230
-
Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours.Clin Oral Investig. 2019 Mar;23(3):995-1006. doi: 10.1007/s00784-018-2524-9. Epub 2018 Jun 20. Clin Oral Investig. 2019. PMID: 29926253
-
Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer.Int J Mol Sci. 2024 Mar 12;25(6):3233. doi: 10.3390/ijms25063233. Int J Mol Sci. 2024. PMID: 38542206 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous